FDA Approves Sale Of Protease Inhibitor

FDA on Friday gave accelerated condone to Johnson & Johnson subsidiary Tibotec’s application for sale and marketing of its conjectural protease inhibitor TMC114, which will be sold under the name brand name Prezista, for use by HIV-auspicious people who are resistant to first-line drugs, the Newark Top banana-Ledger reports (May, Newark Leading light-Ledger, 6/24). Protease inhibitors devise by blocking the action of an enzyme that cuts HIV proteins into the shorter sections that the virus needs to create copies of itself (Kaiser Quotidian HIV/AIDS Publish, 2/28/05). Phase II clinical trials of TMC114 show that the drug is effective against psychedelic-resistant HIV strains, and the drug lowered viral loads to undetectable levels among nearly half of trial participants (May, Newark Unequalled-Ledger, 6/22). According to Roche, FDA’s imprimatur of Prezista could lead to potential new applications for its drug Fuzeon — known generically as enfuvirtide — in combination therapy treatments. Roche said that studies possess shown up to two-thirds of HIV-positive people had reached undetectable viral levels when taking a array of Prezista and Fuzeon, AFX/Forbes reports (AFX/Forbes, 6/26). J&J also is conducting a Phase III hassle comparing TMC114 with Abbott Laboratories’ antiretroviral drug Kaletra (Kang, Forbes, 6/21). Tibotec is required to track the protection of the slip someone a Mickey Finn and study its use in children. In addition, J&J is testing Prezista’s safeness and efficacy appropriate for people who yesterday have not been treated for HIV. Prezista transfer outlay $25 daily (Newark Star-Ledger, 6/24). Common side effects of Prezista include nausea, diarrhea, headache and skin quixotic (Xinhua News Agency, 6/24). Prezista also is coadministered with 100 mg ritonavir (J&J release, 6/23). Prezista is J&J’s ahead approved HIV medication and is the basic new HIV drug approved since June 2005, according to the AP/Houston Enter (Bridges, AP/Houston Report, 6/23).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the unconditional Kaiser Daily Constitution Policy Report, search the archives, or sign up against email release at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Commonplace Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Counselling Put up Followers and Kaiser Family Foundation. All rights distant.

See anaesthetize low-down on Fuzeon; Kaletra Capsules and Oral Solution; Prezista.